Journal of Dermatological Science 27 (2001) 147 – 151
Potential anti-androgenic activity of roxithromycin in skin
Shigeki Inui a,*,1, Takeshi Nakajima a,1, Yoko Fukuzato a, Naohiro Fujimoto b,
Chawnshang Chang b, Kunihiko Yoshikawa a, Satoshi Itami a
a Department of Dermatology, Course of Molecular Medicine, Graduate School of Medicine, Osaka Uni6ersity, Osaka, 2-2, C5,
Yamada-oka, Suita-shi, Osaka 565-0871, Japan
b George H. Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology,
Uni6ersity of Rochester Medical Center, Rochester, 601 Elmwood A6e., Rochester, NY 14642, USA
Received 12 April 2001; received in revised form 23 May 2001; accepted 23 May 2001
Abstract
Since acne formation is a multistep process accelerated by androgens, we examined whether a new anti-acne
antibiotic roxithromycin (RXM) may act as anti-androgen using transient transfection assays in human skinfibroblasts. The result showed no significant effect of 0.5, 1 and 5 mg/ml RXM on 10−9 M R1881-induced androgenreceptor (AR) transcriptional activity. While the cotransfection of exogenous ARA55, a novel AR coactivator,increased AR transactivation up to 2.59-fold, this increase was attenuated by 5 mg/ml RXM to 64.7%. Semiquantita-tive RT-PCR results showed that 0.1 mM H O treatment increased ARA55 mRNA expression level, indicating that
reactive oxygen species increase the expression of ARA55 in skin. These results suggest that RXM may serve asanti-androgen only in the hypersensitive state to androgen, but not in the physiological state, through modulatingend-organ hypersensitive condition to androgen possibly involving the pathway from reactive oxygen species toARA55. 2001 Elsevier Science Ireland Ltd. All rights reserved. Keywords: Acne; Anti-androgen; ARA55
1. Introduction
been used as anti-acne drugs. These antibioticshave been revealed to have not only anti-bacterial
Acne formation is a multistep process, involv-
but also anti-inflammatory properties [3]. How-
ing increased sebum production by androgens
ever, so far it has not been examined whether
[1,2], colonization of Propionibacterium acnes, and
anti-acne antibiotics may act as anti-androgen.
resultant inflammation. The antibiotics against P.
Recently we have cloned out a novel androgen
acnes, such as tetracyclines and macrolides, have
receptor (AR) co-activator ARA55 from humanprostate cDNA library using a yeast two hybridassay system [4]. ARA55 enhances AR transacti-
* Corresponding author. Tel.: + 81-6-6879-3031; fax: + 81-
vation by around five-fold in the prostate cancer
cell line, DU145 cells, indicating that ARA55 may
E-mail address: [email protected] (S. Inui). 1 The first two authors contributed equally to this work.
play important roles in the progression of prostate
0923-1811/01/$ - see front matter 2001 Elsevier Science Ireland Ltd. All rights reserved.
PII: S 0 9 2 3 - 1 8 1 1 ( 0 1 ) 0 0 1 2 9 - 3
S. Inui et al. / Journal of Dermatological Science 27 (2001) 147 – 151
cancer by the modulation of AR activity [4]. We
ethanol as a mock in some experiments. At 48 h
examine here whether ARA55 can exert its func-
after transfection, the cells were harvested for
tion in human dermal fibroblasts and then overex-
luciferase assays. Luciferase activities were mea-
press ARA55 in dermal fibroblasts to recapitulate
sured by the luminometer using the Dual-Luci-
hypersensitive state to androgens in the skin.
feraseTM reporter assay system (Promega). The
Moreover, we evaluate the potential anti-andro-
results were summarized from three independent
genic activity of roxithromycin (RXM), a new
sets of transfection and presented as mean 9SE.
macrolide antibiotic, which have been reported to
In the preliminary study, we confirmed that the
be effective in the treatment of acne [5].
cotransfection of ARA55 has no significant effecton the basal reporter activity without the ligands. 2. Materials and methods
2.4. Re6erse transcription-polymerase chainreaction (RT-PCR)
Cultured human dermal fibroblasts at the sub-
Human dermal fibroblasts were isolated from
confluency were treated with 0.1 mM H O for 2,
skin specimen obtained from plastic surgery oper-
4, 8, 12, and 24 h. Then the cells were harvested
ation and then maintained in Dulbecco’s modified
and total RNA was isolated by acid – guanidinium
Eagle’s medium supplemented with 10% fetal
thiocyanate – phenol – chloroform method. The re-
covery and purity of the RNA was calculatedfrom the optical densities at 260 and 280 nm. One
microgram of total RNA of each sample wasreverse-transcribed using 2.5 mmol/l random hex-
837.06) was supplied by Roussel-Uclaf (Paris,
France). Its stock solution was prepared in
deoxynucleotide triphosphate (dNTP), 1.0 U/ml
Rnase inhibitor (Takara, Tokyo, Japan), and 2.5U/ml M-MLV Reverse Transcriptase (Gibco-
2.3. Transfection and reporter gene assays
BRL). The mixture was incubated at 25 °C for 10min, followed by 42 °C for 45 min, 99 °C for 5
Human dermal fibroblasts were grown in Dul-
min, then 4 °C for 5 min. The resultant DNA was
becco’s modified Eagle’s medium supplemented
amplified using a thermal cycler (Astec, Fukuoka,
with 10% fetal bovine serum. At 50 – 70% conflu-
Japan) in a final volume of 25 ml containing 2
ency in a 24-well plate, the cells were transfected
using lipofectamine plusTM (Gibco-BRL) accord-
HCl, pH 8.3, 0.025 U/ml recombinant Taq DNA
ing to the manufacturer’s instruction. For luci-
polymerase (Takara), and 0.5 mmol/l of each
ferase assays, we transfected 0.3 mg of the reporter
primer. The following sense and antisense primers
plasmids, mouse mammary tumor virus luciferase
(MMTV-Luc) [6]. In some samples, the expression
plasmids for ARA55 and AR, pSG5-ARA55 [4]
and pSG5-AR [6], were co-transfected to the cells.
primers amplifies 633 bp of the C-terminal region
The pRL-CMV vector, the Renilla luciferase con-
of ARA55 [4]. After an initial denaturation at 95
trol reporter vector driven by the CMV immedi-
oC for 9 min, 27 cycles of amplification (denatura-
ate-early enhancer/promoter, was co-transfected
tion at 94 °C for 1 min, annealing at 63 °C for 1
as an internal control. At 24 h after transfection,
min, and extension at 74 °C for 1 min) were
we put fresh medium with methyltrienolone
followed by a terminal extension at 74 °C for 1
(R1881, a synthetic androgen) or ethanol as a
min. These ARA55 primers are the same as we
mock. We also treated the cells with RXM or
have used previously and amplify 633 bp of the
S. Inui et al. / Journal of Dermatological Science 27 (2001) 147 – 151
C-terminal region of ARA55 [4]. PCR amplifica-
3.3. RXM effect on the R1881-induced
tion was performed for 22 cycles (1 min at 94 °C,
transcriptional acti6ity enhanced by ARA55 in
45 s at 60 °C, and 45 s at 72 °C) for glyceralde-
hyde-3-phosphate dehydrogenase (G3PDH) as aninternal control to demonstrate comparable RNA
amounts and quality among samples. The prod-
anti-androgenic function in dermal fibroblasts
without exogenous ARA55 transfection (Fig. 1),
RXM may modulate the AR transactivation en-hanced by ARA55 overexpression. Thus, we
3. Results
transfected 0.3 mg of pSG5-AR and 0.6 mg ofpSG5-ARA55 and examined the effect of 1 and 5
3.1. Effect of RXM on the R1881-induced
mg/ml RXM on R1881-induced transactivation in
transcriptional acti6ity in dermal fibroblasts
dermal fibroblasts. The co-transfection of ARA55increased MMTV-luciferase activity by around
To examine whether RXM can suppress andro-
2.5-fold (Fig. 3, lane 3). Although 1 mg/ml RXM
gen activity in terms of transcriptional regulation,
did not show any significant effect on this en-
we performed luciferase assays using dermal
hanced induction (Fig. 3, lane 4), RXM at the
fibroblasts transiently transfected with 0.3 mg of
concentration of 5 mg/ml suppressed the AR
pSG5-AR. We tested the concentrations from 0.5
transactivation to 64.7% induction (Fig. 3, lane
to 5.0 mg/ml, because 5.0 mg/ml of RXM is consis-
5). These results suggest that RXM has an anti-
tent with the maximal concentration in the serum
androgenic activity under the overexpression of
after taking 150 mg of RXM per os [7]. The result
showed no significant effect of 0.5, 1 and 5 mg/mlRXM on 10−9 M R1881-induced AR transcrip-tional activity (Fig. 1). From this result, RXMdoes not seem to have anti-androgenic effect inskin dermal fibroblast.
3.2. Effect of co-transfection of ARA55 with ARon R1881-induced transacti6ation in dermalfibroblasts
It has been demonstrated that ARA55 potenti-
ates AR transcriptional activity by around five-fold in DU145 cells [4]. To ascertain whetherARA55 can enhance AR transcriptional activityin dermal fibroblast, we examined the effect ofexogenous ARA55 overexpression on R1881-in-duced AR transcriptional activity. pSG5-AR (0.3mg) was transiently transfected into all samples.
Fig. 1. RXM effect on the R1881-induced transcriptional
The co-transfection of 0.3 mg or 0.6 mg pSG5-
activity in dermal fibroblasts without transfection of ARA55.
ARA55 showed 2.35- or 2.59-fold increase in
We transfected 0.3 mg of pSG5-AR and 0.3 mg of MMTV-Luc
R1881-induced AR transcriptional activity (Fig.
into the cell cultured at 50 – 70% confluency in a 24-well plate
2). Although, compared with the ARA55 effect in
using lipofectamine plusTM (Gibco-BRL) and treated with 0.5
prostate cancer cells [4], its effect in dermal
(lane 3), 1 (lane 4) or 5 mg/ml (lane 5) of RXM and 10−9 MR1881 (lanes 2-5) or ethanol as a mock (lane 1). The relative
fibroblasts is relatively weak, it was confirmed
reporter gene activities were compared with the luciferase
that ARA55 can potentiate AR transcriptional
activity in the presence of R1881 and the absence of RXM
S. Inui et al. / Journal of Dermatological Science 27 (2001) 147 – 151
Fig. 2. Exogenous ARA55 effect on the R1881-induced tran-
Fig. 3. RXM effect on the R1881-induced transcriptional
scriptional activity in dermal fibroblasts. We transfected 0.3 mg
activity in dermal fibroblasts with transfection of ARA55. We
of pSG5-AR, 0.3 mg of MMTV-Luc (lanes 1–4), and 0.3 (lane
transfected 0.3 mg of pSG5-AR, 0.3 mg of MMTV-Luc (lanes
3) or 0.6 mg (lane 4) of pSG5-ARA55 into the cells cultured at
1 – 5), or 0.6 mg of pSG5-ARA55 (lanes 3–5) into the cells
50 – 70% confluency in a 24-well plate using lipofectamine
cultured at 50 – 70% confluency in a 24-well plate using lipofec-
plusTM (Gibco-BRL), and treated with 10−9 M R1881 (lanes
tamine plusTM (Gibco-BRL), and treated with 10−9 M
2 – 4) or ethanol as a mock (lane 1). The relative reporter gene
R1881 (lanes 2 – 5) or ethanol as a mock (lane 1). The relative
activities were compared with the luciferase activity in the
reporter gene activities were compared with the luciferase
presence of R1881 and the absence of ARA55 (lane 2).
activity in the presence of R1881 and ARA55 and the absenceof RXM (lane 3).
3.4. H O increases ARA55 mRNA expression in
testosterone and acne severity in women and pro-
posed a model in which variation in skin sensitiv-
Reactive oxygen species (ROS), generated from
ity to androgen and the level of androgen equally
infiltrating neutrophils around the lesions of acne,
contribute to the pathogenesis of acne [9]. Very
has been known to play important roles in the
recently it has been reported no positive correla-
acne formation mainly by progressing inflamma-tion [3,8]. We assumed that ROS may modulateandrogen sensitivity in the skin, possibly throughupregulating the expression of ARA55. To testthis possibility, we treated cultured dermal fibrob-lasts with 0.1 mM H O and examined the change
of ARA55 mRNA expression level by semiquanti-tative RT-PCR. As shown in Fig. 4, ARA55mRNA was gradually increased by the H O
treatment, suggesting that ROS increase the ex-pression of ARA55 and consequently modulateandrogen sensitivity in the skin.
Fig. 4. H O effect on ARA55 mRNA expression in dermal
fibroblasts. Semi-quantitative RT-PCR was performed using
4. Discussion
the same amount of cDNA reverse-transcribed from totalRNA isolated from cultured human dermal fibroblasts treatedwith 0.1 mM H O for 0, 2, 4, 8, 12, and 24 h. The upper
The previous study showed the striking vari-
panel shows the 633 bp products of ARA55 mRNA, and the
ability in the relationship between plasma free
lower shows G3PDH mRNA as the internal controls. S. Inui et al. / Journal of Dermatological Science 27 (2001) 147 – 151
tion between the grade of acne severity and the
this manuscript and Dr Motoko Takahashi at
clinical or laboratory markers of androgenicity
Department of Biochemistry, Graduate School of
tested [10]. From these observations, the end-or-
Medicine, Osaka University, for her useful discus-
gan sensitivity may be a very important factor in
the pathogenesis of acne. In the present study, werecapitulated the hypersensitive state to androgenby overexpression of exogenous ARA55 in vitro. References
Since RXM showed anti-androgenic activity onlyunder overexpression of ARA55, we suggest that
[1] Henze C, Hinney B, Wuttke W. Incidence of increased
RXM serves as anti-androgen only in the state of
androgen levels in patients suffering from acne. Derma-tology 1998;196:53 – 4.
androgen hypersensitivity, but not in the physio-
[2] Akamatsu H, Zouboulis CC, Orfanos CE. Control of
logical state. We showed here that H O treat-
human sebocyte proliferation in vitro by testosterone and
5-alpha-dihydrotestosterone is dependent on the localiza-
suggesting that ROS may modulate androgen sen-
tion of the sebaceous glands. J Invest Dermatol
sitivity through ARA55 in the skin. Therefore,
[3] Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of
RXM may exert the potential anti-androgenic
antibiotics on the generation of reactive oxygen species. J
activity in the hypersensitive state to androgen
such as acne, which has been reported to involve
[4] Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC,
ROS production by neutrophils in the inflamma-
Mizokami A, et al. Cloning and characterization of an-
drogen receptor coactivator, ARA55, in human prostate. J Biol Chem 1999;274:8316 – 21.
So far, the concentration of H O in the tissue
[5] Akamatsu H, Nishijima S, Akamatsu M, Kurokawa I,
of acne in vivo is unknown. Previously it was
Asada Y. Clinical evaluation of roxithromycin in patients
reported that H O at higher concentrations than
with acne. J Int Med Res 1996;24:109 – 14.
0.2 mM triggered apoptosis of dermal fibroblasts,
[6] Hsiao PW, Chang C. Isolation and characterization of
but not at 0.05 and 0.1 mM [11]. Therefore, we
ARA160 as the first androgen receptor N-terminal-associ-ated coactivator in human prostate cells. J Biol Chem
determined for the biological relevance that the
concentration of H O should be 0.1 mM in this
[7] Shiba K, Saito A, Shimada J, Kaji M, Okuda S, Hori S,
study. Since we used skin dermal fibroblasts from
Miyahara T, Matsumoto F, Sakurai I, Hojo T, Ueda Y.
normal human, but not sebocytes from acne pa-
Basic and clinical studies on RU28965. Chemotherapy
tients, it is questionable whether our experimental
[8] Akamatsu H, Horio T. The possible role of reactive
system can reflect the pathological condition of
oxygen species generated by neutrophils in mediating acne
acne inflammation. Further studies using cultured
inflammation. Dermatology 1998;196:82 – 5.
human sebocytes are necessary to conclude our
[9] Reingold SB, Rosenfield RL. The relationship of mild
hypothesis. However, we report here for the first
hirsutism or acne in women to androgens. Arch Dermatol
time that anti-acne antibiotics may have anti-an-
[10] Cibula D, Hill M, Vohradnikova O, Kuzel D, Fanta M,
Zivny J. The role of androgens in determining acneseverity in adult women. Br J Dermatol 2000;143:399 –404.
[11] Bladier C, Wolvetang EJ, Hutchinson P, de Haan JB,
Acknowledgements
Kola I. Response of a primary human fibroblast cell lineto H O : senescence-like growth arrest or apoptosis? Cell
We thank Mrs. Karen Wolf for her helping for
Demande de prise en charge pour Myfortic® et CellCept® Ne pas oublier: remarques et signature du patient en page 2 seules les demandes dûment complétées, bien lisibles et signées pourront être traitées Ce formulaire pourra également être imprimé sous www.svk.org Date de livraison souhaitée ……………………………. Date de livraison souhait�
The aim of this section is to prepare the neuro- everyday neurological practice and to give him logist-in-training for the FMH examination, toor her updates on recent controversies in clinicalconfront her or him with specific problems ofContributions and correspondence to PD Dr. med. Hans H. Jung, Depar tment of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, CH-8091 Zurich, ha